Lag time to benefit, weighed against a composite 83-year-old's estimated prognosis and her own wishes, reshapes one author's view of stopping cancer screening in this NU584 seminar reflection. Searches like "nu 584 unit 5 assignment example", "nu584 unit 5 sample" and "nu584 unit 5 example" land here.
Ageism or Arithmetic? A Reflection on Stopping a Mammogram at 83, and a View Narrowed Rather Than Reversed
[Student Name]
Purdue University Global
NU584: AGNP II - Primary Care of the Frail Elderly
Unit 5 Seminar Reflection
[Instructor Name]
[Date]
The patient is a composite used in the seminar; the prognostic estimate is bracketed.
The View I Brought
I came in believing that stopping cancer screening at a certain age was ageism: a rule that treats older women as not worth the effort. I had seen my own grandmother told she was "too old" for tests she wanted, and I resented it on her behalf.
The Case
Mrs. [R.], 83, lives alone and drives. She has heart failure, with two hospital admissions this year, and a Clinical Frailty Scale level of 5, mildly frail. She asked for her usual mammogram and colonoscopy, "like always."
The Turning Point
A classmate presented a figure I had not known. A meta-analysis of screening trials estimated that about ten years pass before breast or colorectal cancer screening prevents one cancer death for every thousand people screened (Lee et al., 2013). Screening does not help right away; its benefit arrives years later, because it finds cancers that would otherwise have caused harm a decade on.
Another classmate had entered Mrs. [R.]'s details into a prognostic index on ePrognosis, a tool built from published indices for older adults (Yourman et al., 2012). Her estimated likelihood of being alive in ten years was [under 20] percent, largely because of her heart failure.
Set together, the numbers changed the question. The issue was not her age; it was whether she was likely to live long enough for the screening to help her, while she would face its harms now. The harms are immediate: false positives, biopsies, anxiety, and for colonoscopy, bowel preparation that can dehydrate a woman with heart failure and a small risk of perforation or bleeding. The benefit, if it comes, comes after ten years.
The current USPSTF positions reflect this. For breast cancer at 75 and older, the Task Force concluded the evidence could not settle whether mammography does more good than harm (US Preventive Services Task Force, 2024). For colorectal cancer, it recommends selective screening from 76 to 85, based on health, prior screening and preferences (US Preventive Services Task Force, 2021).
The View I Took Away
I no longer think a decision to stop screening is ageism, when it is based on life expectancy and preferences rather than a birthday. A framework for cancer screening in older adults makes exactly this case: estimate life expectancy, weigh the risk of dying from the cancer, weigh the harms of screening, and consider the patient's values (Walter & Covinsky, 2001). An 83-year-old in excellent health, with a long life ahead, might still benefit from screening; Mrs. [R.], with heart failure, probably would not.
But my view was narrowed, not reversed. I still think age alone is a poor reason, and that "too old" is the wrong thing to say. What I resented on my grandmother's behalf was not the decision; it was the reason given and the way it was given. The better conversation explains the time lag, shares the estimate honestly and asks what she wants.
Trying the Conversation
The facilitator asked me to try the conversation with a classmate playing Mrs. [R.]. I began, "You've always kept up with your screening, and I want to talk about whether it still makes sense for you." I explained that screening takes about ten years to help, on average, and that with her heart condition, I could not promise her those years, though I hoped for them. My classmate, in character, said, "So you're saying I'm dying." I said no: I was saying that the tests might put her through a lot now for a benefit that comes much later, and that some women in her position choose to stop and some choose to continue. She asked which I would choose. I said I would want to know what mattered most to her first. She chose to skip the colonoscopy and have one more mammogram. The facilitator said that was a perfectly reasonable outcome.
The Limit
Prognostic indices estimate populations, not individuals, and Mrs. [R.] might outlive her estimate. The decision stays hers. If, after hearing the numbers, she still wants a mammogram, the harms are modest and the choice is reasonable; the colonoscopy, with its preparation and procedure risks, deserves more caution. The goal is an informed choice, not a refusal on her behalf.
What I Will Do
I will talk about time, not age: how long screening takes to help, and how that compares with her likely years. I will use a prognostic tool, share the result as a range, and ask what matters most to her. And I will never say "too old."
References
Lee, S. J., Boscardin, W. J., Stijacic-Cenzer, I., Conell-Price, J., O'Brien, S., & Walter, L. C. (2013). Time lag to benefit after screening for breast and colorectal cancer: Meta-analysis of survival data from the United States, Sweden, United Kingdom, and Denmark. BMJ, 346, e8441. https://doi.org/10.1136/bmj.e8441
US Preventive Services Task Force. (2021). Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA, 325(19), 1965-1977. https://doi.org/10.1001/jama.2021.6238
US Preventive Services Task Force. (2024). Screening for breast cancer: US Preventive Services Task Force recommendation statement. JAMA, 331(22), 1918-1930. https://doi.org/10.1001/jama.2024.5534
Walter, L. C., & Covinsky, K. E. (2001). Cancer screening in elderly patients: A framework for individualized decision making. JAMA, 285(21), 2750-2756. https://doi.org/10.1001/jama.285.21.2750
Yourman, L. C., Lee, S. J., Schonberg, M. A., Widera, E. W., & Smith, A. K. (2012). Prognostic indices for older adults: A systematic review. JAMA, 307(2), 182-192. https://doi.org/10.1001/jama.2011.1966
How this NU584 Unit 5 example is structured
A belief under test organizes the reflection. Its opening part states the author's position precisely, that a screening cutoff by age treats older patients as less worth saving, so the change can be measured against it. Longest of the four, the third part attributes each turn to its source: the facilitator's question about how long benefit takes to arrive, a classmate's lag-time figure, and another classmate's point that harms such as bowel preparation and perforation arrive at once. The author then reframes the objection. Age alone is a poor reason, but time to benefit measured against life expectancy is a good one, and so is her own weighing once both are explained to her. The last part admits what remains unsettled: prognostic indices are imprecise for one person, and a robust 83-year-old may have well over a decade ahead.
Get an NU584 Unit 5 example written to your instructions
Which screening did your Unit 5 seminar argue over? Tell us the case it used, or give us the written route's prompt, plus the rubric. Our reflection states a prior belief, tests it against lag time and the current USPSTF positions, and revises it with a limit. Your first request is free and turns around in 24-48h. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
NU584 Unit 5 questions, answered
What is lag time to benefit?
The interval between starting a preventive intervention and the point at which its benefit becomes measurable. For breast and colorectal cancer screening, a pooled analysis estimated about ten years before one death is prevented per thousand people screened. When a patient's life expectancy is shorter than that lag, the harms of screening arrive without the benefit.
How is life expectancy estimated in a paper?
With a validated index, such as those collected on the ePrognosis site from the University of California, San Francisco, reported with its name and a bracketed result. Some papers use life tables by age and health quartile instead. Either way, state that the estimate applies to groups and may not fit the individual, which graders read as appropriate caution.
Does stopping screening mean stopping all prevention?
No. Vaccinations, fall prevention and some cardiovascular care can deliver benefit within months, and they often remain worth continuing when cancer screening no longer is. A strong reflection makes that distinction, which also answers the worry that older patients are simply being written off once they pass a certain birthday.